The announcement about the recall has come from the U.S. Food and Drug Administration (FDA)
Medwatch service. The notice indicates that all unexpired lots of sterile compounded products are subject to the recall. According to
Newsroom, the sterile products affected are injectable medications, intravenous medicines, eye drops, pellet implants, nasal sprays, inhalation solutions, and eye ointments.
The recall was issued after a single, isolated report of an adverse event involving a patient in California who received a compounded medication from the pharmacy. As a cautionary measure
Abrams Royal decided to voluntarily recall all sterile products within expiry. If there is microbial contamination in products intended to be sterile, patients are at risk for serious, potentially life-threatening infections.
The recalled products were distributed to health care facilities, physicians, and patients from June 17, 2013, through December 17, 2013.
